AzTrials
AzTrials

SeizuresPhase 3RESTORE2NCT00235755

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

A Phase 3 study testing Retigabine in people with Seizures, run by GlaxoSmithKline at 70 sites in 13 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs). Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Seizures
What is being tested?
Retigabine
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
539 participants
Where
70 sitesin 13 countries
Study dates
Dec 2005to Apr 2008
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of refractory epilepsy with simple or complex partial onset seizures with or without secondary generalization
  • 28-day partial seizure frequency rate of four or more partial seizures over the 8-week baseline phase
  • Currently treated with up to three established AEDs
  • Vagal Nerve Stimulator may be included

Who cannot join

  • Existing medical or psychiatric condition which could affect patient's health or compromise ability to participate in the study
  • Clinically significant abnormalities on physical exam, vital signs, ECG, or liver function tests
  • Impaired renal function (creatinine clearance less than 50 mL/minute)
  • Evidence of progressive central nervous disease, lesion, or encephalopathy
  • History of primary generalized seizures
  • History of clustering or flurries or status epilepticus within 12 months of study entry

Trial locations and contacts

70 sites in 13 countries.

70 sites in 13 countries

South Africa9 sites

  • Carl Bremer Hospital

    Belville, West Cape, 7531

  • University of the Free State

    Bloemfontein, Gauteng, 9300

  • Groote Schuur Hospital

    Cape Town, Western Cape, 7925

  • Panorama Medi-Clinic

    Cape Town, 7550

  • Inkosi Albert Luthuli Central Hospital

    Durban, KwaZulu-Natal, 4091

  • Johannesburg Hospital

    Johannesburg, Gauten, 2193

  • Triple M Research

    Port Elizabeth, East Cape, 6001

  • Wilgers MR & Medical Centre

    Pretoria, Gauteng, 0041

  • Sunninghill & Kopano Clinical Trials

    Sunninghill, Gauteng, 2157

Other trials in South Africa

Israel8 sites

  • Barzilai Medical Center

    Ashkelon, 78306

  • Assaf Harofeh Medical Center

    Beer Yaakov, 70300

  • Rambam Medical Center

    Haifa, 31096

  • Wolfson Medical Center

    Holon, 58100

  • Western Galilee Hospital

    Nahariya, 22100

  • Chaim Sheba Medical Center

    Ramat Gan, 52621

  • Kaplan Medical Center

    Rehovot, 76100

  • Tel-Aviv Sourasky Medical Center

    Tel Aviv, 64239

Other trials in Israel

Germany7 sites

  • University of Bonn -- Department for Epileptplogy

    Bonn, D-53105

  • Zentrum Epilepsie Erlangen (ZEE) der Universitaet Erlangen

    Erlangen, BY 91054

  • Georg-August-Universitaet Goettingen

    Göttingen, NI 37075

  • Universitaetsklinik Mainz Neurologische Klinik

    Mainz, RP 55101

  • Universitaet Giessen / Marburg Neurologie

    Marburg, HE 35033

  • Theatinerstrasse 44

    Munich, BY 80333

  • Universitaetsklinikum Ulm

    Ulm, BW 89081

Other trials in Germany

Poland7 sites

  • NZOZ Przychodnia Internistyczno - Stomatologiczna "Kendron"

    Bialystok, 15-420

  • Wojewodzki Szpital Specjalistyczny im.Mikolaja Kopernika

    Gdansk, 80-803

  • Katedra i Klinika Neurologii Slaskiej Akademii Medycznej

    Katowice, 40-752

  • WSS im.Kardynala S. Wyszynskiego

    Lublin, 20-718

  • Specjalistyczna Przychodnia Lekarska Medikard

    Padlewskiego 4, Plock, 09-402

  • Instytut Psychiatrii i Neurologii II Oddzial Neurologii

    Warsaw, 02-957

  • Prywatna Wielospecjalistyczna Lecznica Medyczna "Zycie"

    Warsaw, 03-464

Other trials in Poland

Russia6 sites

  • Interregional Clinical Diagnostic Centre

    Kazan', 420048

  • City Hospital # 1

    Moscow, 117049

  • Clinic of Nervous Diseases of Sechenov's Moscow Med. Academy

    Moscow, 119021

  • District Antiepileptic Centre City Clinical Hospital # 71

    Moscow, 121374

  • Military Medical Academy n.a. S.M.Kirov

    Saint Petersburg, 194044

  • St.Petersburg State Medical University n.a. I.P.Pavlov

    Saint Petersburg, 197022

Other trials in Russia

Spain6 sites

  • Hospital de La Santa Creu i Sant Pau

    Barcelona, 08025

  • Hospital de Cruces

    Bilbao, 48903

  • Hosp de Donostia

    Donostia / San Sebastian, 20014

  • Hosp. Virgen de las Nieves

    Granada, 18013

  • Hospital Ruber Internacional de Madrid

    Madrid, 28034

  • Hosp. Clinico Univ. Lozano Blesa

    Zaragoza, 50009

Other trials in Spain

Australia5 sites

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, 2050

  • Monash Medical Centre

    Clayton, Victoria, 3168

  • North Coast Neurology Centre

    Maroochydore, Queensland, 4558

  • Royal Melbourne Hospital

    Parkville, Victoria, 3050

  • Austin & Repatriation Medical Centre

    West Heidelberg, Victoria, 3084

Other trials in Australia

Ukraine5 sites

  • Psychosomatic Center of Dnepropetr. Regional Clinic

    Dnipro, 49616

  • Kharkiv State Medical University

    Kharkiv, 61022

  • Institute of Neurology, Psychiatry and Narcology of AMS, Ukr

    Kharkiv, 61068

  • Epilepsy Center of Municipal Clinical Psychoneurological Hospital

    Kiev, 04080

  • Odessa Regional Clinical Hospital

    Odesa, 65025

Other trials in Ukraine

United Kingdom5 sites

  • Fylde Coast Hospital

    Blackpool, LANARK FY3 8BP

  • Western Infirmary (Epilepsy)

    Glasgow, G11 6NT

  • Walton Centre for Neurology & Neurosurgery

    Liverpool, L9 7LJ

  • Royal London Hospital

    London, GT LON E1 1BB

  • The James Cook University Hospital

    Middlesbrough, Mersyd, T&W TS4 3BW

Other trials in United Kingdom

Belgium4 sites

  • A. Z. Middelheim -- Department of Neurology

    Antwerp, 2020

  • AZ Sint-Jan

    Bruges, 8000

  • Universitaire Ziekenhuizen Gasthuisberg -- Department Neurology

    Leuven, 3000

  • Centre Neurologique William Lennox

    Ottignies, 1340

Other trials in Belgium

France4 sites

  • Hopital Neurologique Pierre Wertheimer

    Lyon, Lyonnais, 69003

  • CHU Pontchaillou

    Rennes, 35033

  • Hopital Civil de Strasbourg

    Strasbourg, 67 67091

  • Centre Medical de La Teppe

    Tain-l'Hermitage, 26 26600

Other trials in France

United States2 sites

  • Mid-Atlantic Epilepsy and Sleep Center

    Bethesda, Maryland, 20817

  • Neurological Clinic-Texas

    Dallas, Texas, 75230

Other trials in United States

Hungary2 sites

  • Natl. Inst. of Psychiatry and Neurology

    Budapest, 1021

  • Orszagos Idegsebeszeti Tudomanyos Intezet

    Budapest, 1145

Other trials in Hungary

About this study

Official title: Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures

This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs).

Read the detailed description

This Phase 3 study is being conducted in Europe, Israel, Australia, and South Africa to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs). The primary objective is to demonstrate a superior change in total partial seizure frequency for four weeks from baseline to the double-blind period. The proportion of responders (greater than or equal to 50% reduction in seizure frequency for four weeks from baseline to the double-blind period) will also be evaluated.

Conditions
Seizures
Being tested
Retigabine, Placebo
Keywords
Partial Seizures, Complex Partial Seizures, Epilepsy, Potassium Channels, Anticonvulsant
Medical subject headings
Seizures, Epilepsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RetigabineDrug

    Also called GKE-841, D-23129

    Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.

  • RetigabineDrug

    Also called GKE-841, D-23129

    Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.

  • PlaceboDrug

    Oral tablet.

Study groups in NCT00235755
Study groupRoleWhat they receive
PlaceboPlacebo comparatorNot described
Receives: Drug: Placebo
Retigabine 600 mgExperimentalNot described
Receives: Drug: Retigabine
Retigabine 900 mgExperimentalNot described
Receives: Drug: Retigabine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)

    28-day total PS (PSs [also called focal seizures] are seizures limited to a specific area of the brain) frequency in the BL period = (Number [No.] of total PSs reported in the BL period divided by the No. of days of available total PS data in the BL period) x 28 days. 28-day total PS frequency in the DB period = (No. of total PSs reported in the DB period divided by the No. of days of available total PS data in the DB period) x 28 days. Percent change = ([value in the DB period minus value at BL] divided by the BL value) x 100%. Negative valu es indicate a reduction in seizure frequency.

    Measured: Baseline (Week -7 through Week 0), DB Phase (Week 1 through Week 16)

  2. Number of Participants Classified as Responders and Non-responders During the Maintenance Phase

    Responders were participants with at least a 50% reduction in the 28-day total partial seizure frequency in the Maintenance Phase as compared to the Baseline period.

    Measured: Week 5 through Week 16

Secondary outcomes (18)

  1. Number of Participants Who Were Responders and Non-responders During the DB Phase

    Responders were participants with at least a 50% reduction in the 28-day total partial seizure frequency in the DB Phase as compared to the Baseline period. Participants without any post-baseline data were considered non-responders.

    Measured: Week 1 through Week 16

  2. Percent Change From Baseline (BL) in the 28-day Total Partial Seizure Frequency During the Maintenance Phase

    28-day total partial seizure frequency in the BL period = (No. of total partial seizures reported in the BL period divided by the No. of days of available total partial seizure data in the BL period) x 28 days. 28-day total partial seizure frequency in the Maintenance Phase = (No. of total partial seizures reported in the Maintenance Phase divided by the No. of days of available total partial seizure data in the same phase) x 28 days. Percent change = (value in the Maintenance Phase minus value at BL divided by the BL value) x 100%. Negative values indicate a reduction in seizure frequency.

    Measured: Baseline (Week -7 through Week 0), Week 5 through Week 16

  3. Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories

    Participants who experienced a reduction from Baseline in the 28-day total partial seizure frequency were categorized as having a reduction of 75-100%, 50-<75%, 25-<50%, or <25%, in addition to having no reduction. This quartile cutting was specified in the study protocol. Participants without any post-baseline data are included in the "No reduction" category.

    Measured: Baseline (Week -7 through Week 0), Week 1 through Week 16

  4. Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the DB Phase (Titration and Maintenance Phases) by Indicated Decile Reduction and Increase Categories

    Participants who experienced a reduction from Baseline in the 28-day total partial seizure frequency were categorized in decile cutting, i.e., reduction categories of 90-100%, 80-<90%, 70-<80%, 60-<70%, 50-<60%, 40-<50%, 30-<40%, 20-<30%, 10-<20%, >0-<10%, and increase categories of 0-10%, >10-20%, >20-30%, >30% (FDA endpoint). Participants without any post-baseline data were included in the category 0-10% increase category.

    Measured: Baseline (Week -7 through Week 0), Week 1 through Week 16

  5. Number of Participants With the Indicated Reduction From Baseline in the 28-day Total Partial Seizure Frequency During the Maintenance Phase

    Participants who experienced a reduction from Baseline in the 28-day total partial seizure frequency were categorized as having a >75%, a 50-75%, or a <50% reduction, in addition to having no reduction (EMEA endpoint).

    Measured: Baseline (Week -7 through Week 0), Week 5 through Week 16

  6. Number of Participants Who Experienced the Indicated Level of Exacerbation and Reduction in the 28-day Total Partial Seizure Frequency From Baseline During the Maintenance Phase

    Participants who experienced an exacerbation from Baseline in the 28-day total partial seizure frequency were categorized as having a 0-25% or a >25% increase (EMEA endpoint). The number of participants experiencing a >0% reduction from Baseline in the 28-day total partial seizure frequency are also presented.

    Measured: Baseline (Week -7 through Week 0), Week 5 through Week 16

  7. Number of Participants Reporting New Seizure Types in the Indicated Categories During the DB Phase (Titration and Maintenance Phases) That Were Not Reported at Baseline

    New seizure types included those seizures which were not reported by any participant at Baseline.

    Measured: Baseline (Week -7 through Week 0), Week 1 through Week 16

  8. Number of Participants Who Were Seizure-free During the DB Phase (Titration and Maintenance Phases)

    Participants were considered to be seizure-free if they had not reported any seizures during the DB treatment period (Weeks 1-18). For a participant to be seizure free during the DB Phase, the participant had to be seizure free both Week 7 to Week 18 and Week 1 to Week 6. A participant could be seizure free Week 7 to Week 18 (during the Maintenance Phase), but not seizure free Week 1 to Week 6. Hence, there are fewer participants being reported as seizure free from Week 1 to Week 18 than from Week 7 to Week 18.

    Measured: Week 1 through Week 16

  9. Number of Participants Who Were Seizure-free During the Maintenance Phase

    Participants were considered to be seizure-free if they had not reported any seizures during the Maintenance Phase.

    Measured: Week 5 through Week 16

  10. Percentage of Seizure-free Days During the DB Phase (Titration and Maintenance Phases)

    A seizure-free day was a day without any seizures. For a participant to be seizure free during the DB Phase, the participant had to be seizure free both Week 7 to Week 18 and Week 1 to Week 6. A participant could be seizure free Week 7 to Week 18 (during the Maintenance Phase), but not seizure free Week 1 to Week 6. Hence, there are fewer participants being reported as seizure free from Week 1 to Week 18 than from Week 7 to Week 18. The percentage of seizure-free days was calculated as the total number of days without seizures in the DB period divided by the number of days in DB period x 100%.

    Measured: Week 1 through Week 16

  11. Percentage of Seizure-free Days During the Maintenance Phase

    A seizure-free day was a day without any seizures. The percentage of seizure-free days was calculated as the total number of days without seizures in the Maintenance Phase divided by the number of days in the Maintenance Phase x 100%.

    Measured: Week 5 through Week 16

  12. Clinical Global Impression-Improvement (CGI-I) Score at the End of the Maintenance Phase

    Clinical Global Impression of Improvement (CGI-I) is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the treatment. Scores on the scale are rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.

    Measured: Week 16/end of treatment phase

  13. Patient Global Impression (PGI) Score at the End of the Maintenance Phase

    PGI is a participant-rated scale of improvement that was administered at the end of the Maintenance Phase in order to assess the participant's impression of his or her own improvement. PGI assessments were scored using a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.

    Measured: Week 16/end of treatment phase

  14. Quality of Life Assessed by Quality of Life in Epilepsy-Problems Questionnaire (QOLIE-31-P) at BL (Week 0) and Weeks 4, 8, and 16

    The QOLIE-31-P is a 31-item questionnaire evaluating a participant's QOL perception in 7 domains: seizure worry, emotional well being, energy/fatigue, cognitive functioning, medication effects, social functioning, overall QOL. Precoded numeric values for some domains are such that a higher number reflects a more favorable health state; others are such that a higher number reflects a less favorable state. Precoded values are first converted to 0-100 point scores; higher converted scores always reflect better QOL. The overall score is derived by weighting and then summing the 7 domain scores.

    Measured: End of Baseline (Week 0), Weeks 4, 8, and 16

  15. Number of Participants Whose Clinical Laboratory Values Were Deemed an Adverse Event by the Investigator (>=2% in Any Treatment Arm)

    Clinically important changes in laboratory values were to be reported as an adverse event if they met one of the following criteria: (1) intervention required; (2) change in dose of study drug required; (3) other treatment/therapy required; (4) association with other diagnoses.

    Measured: Week 1 through Week 16

  16. Number of Participants Who Reported the Indicated Renal and Urinary Disorder Adverse Events at a Frequency Threshold of 2% (in Any Treatment Arm)

    A summary of the adverse events classified as renal or urinary disorders and in which at least 2% (rounded to an integer) of participants in any treatment arm reported during the study is presented.

    Measured: Week 1 through Week 16

  17. Change From Baseline in Post-void Residual Urine Volume at Weeks 8 and 16 of the Maintenance Phase

    Post-void residual (PVR) urine refers to the amount of urine remaining in the bladder after normal urination. To investigate the possible effects of retigabine on bladder function, all participants underwent post-void residual bladder ultrasound at Baseline and during the Maintenance Phase. The PVR bladder ultrasound was performed by a urologist, a qualified ultrasound technician, or a qualified study nurse who was certified to do PVR bladder ultrasound. Change from Baseline in PVR residual volume was calculated as the values at Week 10 and Week 16 minus the value at Baseline.

    Measured: Baseline (Week -7 through 0), Weeks 8 and 16

  18. Number of Participants With a >=7% Increase in Body Weight During Weeks 2 and 4 of theTitration Phase and Weeks 6, 8, 12, and 16 of the Maintenance Phase

    The number of participants with recorded weight gain of >=7% over their baseline weight was measured.

    Measured: Weeks 2 and 4 of Titration Phase and Weeks 6, 8, 12, and 16 of Maintenance Phase

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Oct 2005 (estimated)
  2. Study startDec 2005
  3. Primary completionApr 2008
  4. Study completionApr 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
539 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00235755
Sponsor's protocol ID
VRX-RET-E22-302
Acronym
RESTORE2
Status last verified
Mar 2017
First submitted
6 Oct 2005
Last updated
21 Apr 2017
Data monitoring committee
No

Publications

  • Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, Nohria V, Mansbach H; RESTORE 2 Study Group. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010 Nov 16;75(20):1817-24. doi: 10.1212/WNL.0b013e3181fd6170. Epub 2010 Oct 13.

    PubMed 20944074

  • Tompson DJ, Crean CS. Clinical pharmacokinetics of retigabine/ezogabine. Curr Clin Pharmacol. 2013 Nov;8(4):319-31. doi: 10.2174/15748847113089990053.

    PubMed 23342983

  • Brickel N, Gandhi P, VanLandingham K, Hammond J, DeRossett S. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12. doi: 10.1111/j.1528-1167.2012.03441.x. Epub 2012 Mar 16.

    PubMed 22428574

  • Porter RJ, Burdette DE, Gil-Nagel A, Hall ST, White R, Shaikh S, DeRossett SE. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials. Epilepsy Res. 2012 Aug;101(1-2):103-12. doi: 10.1016/j.eplepsyres.2012.03.010. Epub 2012 Apr 16.

    PubMed 22512894

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Retigabine in people with Seizures, run by GlaxoSmithKline at 70 sites in 13 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 70 sites in South Africa, Israel, Germany, Poland, Russia and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 7 Nov 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases) (time frame: Baseline (Week -7 through Week 0), DB Phase (Week 1 through Week 16)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00235755, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2017.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in